Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies

Oded Shamriz*, Yuval Tal, Aviv Talmon, Amit Nahum

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Children with chronic mucocutaneous candidiasis (CMC) experience recurrent infections with Candida spp. Moreover, immune dysregulation in the early life of these patients induces various autoimmune diseases and affects normal growth and development. The adaptive and innate immune system components play a significant role in anti-fungal response. This response is mediated through IL-17 production by T helper cells. Inborn errors in IL-17-mediated pathways or Candida spp. sensing molecules are known to cause CMC. In this review, we describe underlying immune mechanisms of monogenic primary immune deficiency disorders known to cause CMC. We will explore insights into current management of these patients and novel available therapies.

Original languageEnglish
Article number593289
JournalFrontiers in Immunology
Volume11
DOIs
StatePublished - 16 Oct 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© Copyright © 2020 Shamriz, Tal, Talmon and Nahum.

Keywords

  • autoimmunity
  • chronic mucocutaneous candidiasis
  • CMC
  • immune dysregulation
  • primary immune deficiency

Fingerprint

Dive into the research topics of 'Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies'. Together they form a unique fingerprint.

Cite this